{"id":788654,"date":"2026-07-08T17:22:09","date_gmt":"2026-07-08T17:22:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/788654\/"},"modified":"2026-07-08T17:22:09","modified_gmt":"2026-07-08T17:22:09","slug":"q-a-mg-exacerbation-and-pregnancy","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/788654\/","title":{"rendered":"Q &#038; A: MG Exacerbation and Pregnancy"},"content":{"rendered":"<p style=\"font-weight: 400;\">In this interview, Anna Rostedt Punga, MD, PhD, shares insight regarding myasthenia gravis (MG) worsening in women who become pregnant or who have recently given birth. Here, she discusses general trends, clinical monitoring strategies, and medical safety tips for this patient population.<\/p>\n<p style=\"font-weight: 400;\">Rare Diseases Today:\u00a0\u00a0Please introduce yourself to our audience by sharing your name, title, affiliation, and role in the research.<\/p>\n<p style=\"font-weight: 400;\">Dr. Punga: My name is Anna Rostedt Punga, MD, PhD, a professor and consultant in clinical neurophysiology at Uppsala University Hospital in Sweden. I served as the senior study author and oversaw the investigation.<\/p>\n<p style=\"font-weight: 400;\">Rare Diseases Today:\u00a0\u00a0Your analysis found no increased risk of MG exacerbation during pregnancy, but a higher risk of prolonged exacerbations post partum. How should clinicians interpret this difference when counseling patients before conception and during peripartum care?<\/p>\n<p style=\"font-weight: 400;\">Dr. Punga: Our findings are overall reassuring for women with MG who are considering pregnancy. We did not observe any evidence for increased risk of MG-related hospitalization or a greater need for immunosuppressive therapy for MG during pregnancy. Among the 112 women in the study, 16 experienced an exacerbation requiring hospitalization after one of their pregnancies. Importantly, more than half of these women had another pregnancy without such complications, indicating that the interaction between MG and the immune changes associated with the postpartum period is complex, and it is a difficult challenge to predict who will get an exacerbation post partum.\u00a0Counseling should include assuring women that they will be closely monitored after delivery and encouraging them to report any symptoms promptly.<\/p>\n<p style=\"font-weight: 400;\">Rare Diseases Today:\u00a0\u00a0Given that postpartum exacerbations appeared more severe or prolonged in a subset of patients, what clinical monitoring strategies or follow-up intervals do you recommend in the first 3 to 12 months after delivery?<\/p>\n<p style=\"font-weight: 400;\">Dr. Punga: \u00a0At present, we would not recommend a single standardized follow-up schedule for all patients. Instead, monitoring should be individualized based on clinical factors such as disease stability and prior history.<\/p>\n<p style=\"font-weight: 400;\">We did include a table in our study with the clinical characteristics, including Myasthenia Gravis Foundation of America Clinical Classification, antibody serology, of the women who experienced exacerbations. But again, considering that exacerbation was not consistent across pregnancies\u00a0in the same woman, we cannot, at this point, give any reliable clinical characteristics that can predict postpartum exacerbation. This will be an individualized decision between the woman and her neurologist, based initially on local hospital guidelines and on closer follow-up intervals for women with disease instability.<\/p>\n<p style=\"font-weight: 400;\">Rare Diseases Today: The study relied on hospitalizations as a proxy for exacerbation. How might this approach underestimate milder disease activity, and how should clinicians account for this limitation in real-world management?<\/p>\n<p style=\"font-weight: 400;\">Dr. Punga:\u00a0 Using hospitalization as a proxy likely underestimates milder exacerbations. Patients with less severe worsening, detected through clinical scores, like Myasthenia Gravis Composite or Quantitative Myasthenia Gravis, or self-reported symptoms via the Myasthenia Gravis Activities of Daily Living assessment, may not have been captured. In clinical practice, this underlines the importance of not relying solely on severe outcomes. Physicians should perform regular clinical assessments and actively inquire about symptoms throughout pregnancy and the postpartum period.<\/p>\n<p style=\"font-weight: 400;\">Rare Diseases Today: You observed changes in immunosuppressive therapy during pregnancy and postpartum. What practical guidance can you offer clinicians on balancing disease control with medication safety in this population?<\/p>\n<p style=\"font-weight: 400;\">Dr. Punga:\u00a0 We observed reductions in immunosuppressive therapy in 13 pregnancies and an increase in six pregnancies. During pregnancy and post partum, medications were increased in 10 pregnancies and reduced in none. This again suggests disease stability during pregnancy, with postpartum exacerbations in a minority of women. Importantly, none of the women in our cohort used known teratogenic medications during pregnancy. This supports the principle that treatment strategies must carefully balance disease control with fetal safety, ideally through preconception planning.\u00a0<\/p>\n<p style=\"font-weight: 400;\">Rare Diseases Today: Your data suggest that many women may conceive during periods of relative disease stability. How should this inform shared decision-making and timing of pregnancy in patients with myasthenia gravis?<\/p>\n<p style=\"font-weight: 400;\">Dr. Punga:\u00a0 Our data suggest that many women conceive during periods of relative disease stability, which is generally advisable. Although this cannot always be planned, the first 2 years after MG diagnosis are often considered a higher-risk period for disease fluctuations.<\/p>\n<p style=\"font-weight: 400;\">At the same time, decisions about pregnancy are highly individual. Factors such as maternal age, disease status, and personal preferences must all be considered in shared decision-making between the woman and her physician.<\/p>\n","protected":false},"excerpt":{"rendered":"In this interview, Anna Rostedt Punga, MD, PhD, shares insight regarding myasthenia gravis (MG) worsening in women who&hellip;\n","protected":false},"author":2,"featured_media":788655,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[49,48,84],"class_list":["post-788654","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-ca","tag-canada","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/788654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=788654"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/788654\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/788655"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=788654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=788654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=788654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}